← SynDRA
MILTEFOSINE
SynDRA canonical compound SYN0001197 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | PLA2G1B |
|---|
| Mechanism of action | membrane integrity inhibitor |
|---|
| Indication | leishmaniasis |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- AKT1 INHIBITOR
- membrane integrity inhibitor
- PLA2G1B INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADRA1A
- ADORA1
- HTR2B
- MC3R
- LMNA
- KCNH2
- KAT2A
- HTR3A
- HTR2C
- HTR2A
- NPY1R
- HTR1A
- HRH3
- HRH2
- HRH1
- HMBS
- MLNR
- NR1I2
- GMNN
- NR3C1
- OPRD1
- OPRK1
- OPRM1
- PDE3A
- PDE4D
- PGR
- PTGS2
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- SLCO1B1
- SLCO1B3
- HDAC6
- GHSR
- ADORA2A
- FECH
- ADORA3
- ADRA2A
- ADRA2B
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP3A7
- GPR32
- HEXB
- JUN
- KSYK
- NR1H4
- NSD2
- SMAD2
- SMAD3
- SYK
Drug classes
- Anti-Infective Agents
- Antifungal Agents
- Antineoplastic Agents
- Antiparasitic Agents
- Antiprotozoal Agents
- Antileishmanial
ATC classes
- P01C · AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS
Cross-references
Synonyms
- IMPAVIDO
- Impavido
- impavido
- hexadecylphosphocholine
- hexadecylphosphorylcholine
- miltefos
- Miltefosina
- D-18506
- NSC-605583
- NSC-758968
- Miltex
- HDPC
- HePC
- Hexadecylphosphocholine
- Hexadecylphosphorylcholine
- Miltefosinum
- Baxter Oncology brand of miltefosine
- Baxter brand of miltefosine
- Miltefosin C
- Prasfarma brand of miltefosine
- IN1227
- H-1850
- M-7200
- Miltefosina [INN-Spanish]
- Miltefosine (INN)
- Miltefosine[INN:BAN]
- Miltefosinum [INN-Latin]
- N-Hexadecylphosphorylcholine
- TF-002
- Choline hydroxide, hexadecyl hydrogen phosphate, inner salt
- Choline, hexadecyl hydrogen phosphate, inner salt
- Hexadecyl 2-(trimethylazaniumyl)ethyl phosphate
- Choline phosphate, hexadecyl ester, hydroxide, inner salt
- Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI)
- Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt
- Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt
- 1-Hexadecylphosphorylcholine
- 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt
Reported adverse events
- Asthenia
- Dizziness
- Headache
- Lymphangitis
- Malaise
- Nausea
- Pruritus
- Pyrexia
- Somnolence
- Stevens-Johnson syndrome
- Vomiting
Look up MILTEFOSINE in the interactive SynDRA portal →